Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emisphere Technologies has announced positive results from the additional animal studies which demonstrated that the company's proprietary eligen technology enhances the absorption of oral B12 at considerably lower doses than were used previously.
Subscribe to our email newsletter
The lower doses are believed to be more physiologically relevant. The data showed that the rate of absorption of B12 administered with eligen increased significantly 26 to 34 minutes, compared with 72 minutes for B12 administered alone. Confirming the original study, overall absorption of B12 using eligen technology was 18 times greater than with the same dose administered alone.
Michael Novinski, president and CEO of Emisphere, said: “This new data not only confirms our original findings, but is a step forward in our plan to commercialize our eligen technology. These studies validate our belief in the efficacy of the technology and enable us to move toward human clinical studies as early as the beginning of the third quarter of this year.”